



Syringex Medical, Inc.
31511 2nd Avenue SW
Federal Way, WA 98023
Phone: 253-838-8547
Fax: 253-838-8549
Email: info@syringex.com

The information set forth in this document includes confidential business information of Syringex Medical, Inc. ("the Company" or "SMI") and is provided in connection with a potential transaction between the Company and one or more accredited investors, within the meaning of applicable securities laws. This

document does not constitute an offer, or a solicitation of an offer, for the sale of securities. Any such offer, solicitation, or sale shall only be pursuant to definitive documentation, acceptable to the parties of the transaction, in their respective discretion. Included herein are certain internal projections of possible future financial results for the Company. The Company does not warrant the accuracy or completeness of the projections or the reasonableness of the assumptions underlying such projections, although the Company believes such assumptions to be reasonable. Any potential investors in the Company are advised to conduct their own investigations, to their satisfaction, with respect to the business and affairs of the Company.

INFORMATION PROFILE

25 September 2006

EVERY YEAR

- 1 million healthcare workers in the U.S. are stuck with hypodermic needles that may be infected with Hepatitis B, Hepatitis C or HIV.
- Over 1000 of them contract serious infections.
- Over 80% of these injuries could be prevented.
- In some countries as many as 90% of the injections given are unsafe.
- 24 million people in developing countries around the world are infected yearly.
- More than 580 million people in the world are chronic carriers of these diseases.
- An estimated 1.3 to 1.6 million die.
- Countless others in the private sector including housekeepers, janitors, and trash handlers are not even counted in these statistics.
- The medical community was aware of this problem for years.

SO WHY WASN'T A SOLUTION PUT INTO PLACE ASAP?

- Purchasing decisions were made primarily on cost.
- Purchasing contracts set up with major group purchasing organizations (GPOs) limited the choices.
- Existing syringe manufacturers were reluctant to invest in new designs.
- And, why change? They already controlled the industry.

SOMETHING NEEDED TO BE DONE

- Frontline medical professionals were the first to demand safer syringes.
- In April of 1998 the San Francisco Chronicle printed the "Deadly Needle Series", putting California legislators on notice.
- In September, 1998 Cal/OSHA passed the first legislation mandating the use of safety needle products in California.
- In November of 2000 President Clinton signed the Federal Needlestick Safety and Prevention Act requiring the use of safety devices.
- Purchasing decisions in hospitals are no longer based solely on cost.
- Purchasing agents are now required to listen to needlestick committees comprised of medical professionals; and they want something effective.
- 23 states have passed additional needlestick legislation and 17 states currently have legislation pending.
- Group purchasing organizations have been brought before the US senate for their monopolistic practices.
- Retractable Technologies filed and prevailed in an antitrust suit against Premier, Novation, and Kendall Healthcare. The settlement terms were undisclosed.
- The case with the fourth defendant, BD, settled out of court for \$100 million.
- These events are causing the major syringe manufacturers to lose their grip on market domination.
- The stage is set for smaller manufacturers to enter the market.
- Outside the United States markets are beginning their own transition to safety engineered devices.

THE COST OF SYRINGES

STANDARD SYRINGES

- Standard, disposable 3cc syringes sell for about \$.15 retail.
- Quantity discounts drop their price to about \$.09 or \$.10.

SAFETY SYRINGES

- Safety syringe products are marketed at a higher price than the standard syringe creating a market more than twice the size.
- 3cc safety syringes currently range from \$.29 to \$1.06 in 100 quantities.
- BDs sheathed Safety Lok, their cheapest safety syringe, just went up from \$.21 to \$.23 at a major GPO.

THE MARKET

U.S. AND WORLD SYRINGE MARKETS.

- The US market is almost 7 billion syringes per year.
- The European market has been estimated at over 6 billion units.
- The Chinese market is estimated at over 5 billion per year.
- The total worldwide syringe market has been estimated as high as 30 billion syringes.

UNITED STATES

- Penetration of safety syringes in the US in 2002 was at about 24% of the total syringe market, or more than \$300 million.
- Double digit growth is predicted through 2009 by Frost & Sullivan.
- The U.S. market is expected to grow to over \$2 billion with the conversion to safety syringes.

WORLDWIDE

- Market experts; agree that the standard syringe will be replaced by the safety syringe on a global basis.
- Worldwide the standard syringe market was \$2.5 billion in 1998.
- Conversion to safety syringes is expected to expand the market to more than \$5.5 billion.

THE COST OF CHANGE

- The cost of needlestick injury follow-up in the U.S. per incident is around \$3,000.
- Accident follow ups cost the US medical industry \$1.2 billion annually.
- Annual treatment for contracted diseases in the US is \$1.8 billion.
- This is a total of \$3 billion spent annually in the US on needlestick injuries.
- This is three times the amount spent on conventional syringes.
- And almost 3 times the cost of converting to safety syringes.

U.S. MARKET SHARE OF STANDARD SYRINGES VS SAFETY SYRINGES

THE 1998 MARKET SHARE OF *STANDARD SYRINGES* IN THE US:

Becton Dickinson 71%
Kendall Healthcare 22%
Others 7%

THE 2002 MARKET SHARE OF *SAFETY SYRINGES* IN THE US:

Becton Dickinson 54%
Kendall Healthcare 21%
Portex 10%
Others 15%

The balance of power is in transition, and the stage is set for the right product to gain more market share than has been achievable in recent history.

COMPETITION COMPARISON

THERE ARE CURRENTLY FOUR GENERAL TYPES OF SAFETY SYRINGES.

- Sheathing tube syringes

- Sliding needle covers
- Hinged needle Covers; and
- Spring retractable syringes

SHEATHING TUBE SYRINGES

BD Safety-Lok - \$.29

Kendall Monoject - \$.27

- Require two hands to operate.
- Require a second hand moving closer to the needle to activate them.
- Harder to read the scales because of the sheath.
- Many reported problems of being able to reliably engage the safety mechanisms.
- Must retract from the injection site, exposing the needle before actuation.
- Take up more room in expensive sharps containers.
- Use of the BD Safety-lok syringe increased needlesticks at Kaiser Permanente.
- The Kendall syringe requires a second operation in order to lock it in place. The same old problem - with a new twist.

SLIDING NEEDLE COVERS

BD Safety Glide - \$.50

Kendall Magellan - \$.37

- Require a grip change.
- Safety feature actuation requires a thumb or finger in closer proximity to the needle.
- Must retract from the injection site, exposing the needle before actuation.
- Kaiser's use of the BD SafetyGlide failed to reduce needle sticks during one year of wide-spread use.

HINGED NEEDLE COVERS

BD Eclipse - \$.39

Terumo Surguard - \$.52

- Necessitate reaching next to the needle to move the cover out of the way in order to give an injection.
- Require a grip change to operate a safety feature.
- Puts at least one finger in close proximity to the needle after the injection.
- Must retract from the injection site, exposing the needle before actuation.
- Cumbersome to use.
- Flipping motion as the needle snaps into the cover can cause blood splatter.

SPRING RETRACTABLE SYRINGES

NMT - \$.68

Vanishing Point - \$.65

BD Integra - \$.72

- Splatter on activation.
- Aerosol residual contents, potentially spreading contagious viruses.
- Difficult to actuate, requiring over 9 lbs of push.
- Actuation can cause movement of the needle resulting in tissue trauma.
- Weak springs don't always pull the needle out of the patient.
- The needle hanging up in the muscle and skin flips back, splattering the needle's contents on the operator.
- Viruses can be picked up through contact with the eye, nose, mouth, or skin.

OTHER DISADVANTAGES OF THE COMPETITORS' SAFETY SYRINGES

- Difficult to learn to use.
- Require extensive training.
- Lack of instructions on the device pouches.
- Lack of confirmation that the safety mechanism is locked.
- Many safety syringes are currently discarded in sharps containers without actuation because they are difficult or cumbersome to activate.
- As a group they give healthcare workers a false sense of security.
- Calling them Safety Syringes is a major misnomer.

The lack of instructions on the pouches is a real problem at hospitals, where medical professionals grab a syringe out of a bulk bin. Many syringes are packaged in pouches that don't break open and the operator is

required to fumble with the “peel open” corner. This can be a real problem when a syringe is required rapidly in an emergency.

Note: Prices listed above are the highest quantity prices listed by Henry Schein and Moore Medical for comparison purposes.

SYRINGEX SAFETY SYRINGE

ADVANTAGES OF THE SYRINGEX SAFETY SYRINGE

- No splatter or aerosol.
- Actuation requires just over 1 lb of force.
- No danger of tissue trauma.
- Low cost.
- Fewer needle sticks.
- Simple and intuitive to use.
- Instructions are printed on the rip through pouch.
- The needle is retracted directly from the patient into the barrel of the syringe.
- A “snap feel” confirms actuation of the safety feature.
- The operator can see the needle safely retracted into the barrel.
- Graduation lines are easy to read.
- Hands and fingers stay behind the front of the syringe.
- Lower disposal costs. It doesn’t take up any additional room in sharps containers.

The combined major benefits of the Syringex Safety Syringe are improved ease of operation and safety through simplicity of design and use.

- There was an overwhelming preference for our safety syringe during Syringex Medical’s clinical trials.
- The clinical trial participants stated that they would change to our syringe as soon as it was available.
- Demonstrations to other medical professionals have elicited the same favorable response.

NEW PRODUCTS BEING DEVELOPED IN THE NEAR FUTURE

- An expanded syringe line.
- A line of irrigation syringes.
- Additional safety products - IV, catheter, dental syringes, and safety blood draw designs.
- Medical diagnostic tools for physicians.

MARKETING PLAN

Establishing product and company name recognition are a must as is product demonstration showing the advantages over major competitors. This must be done while the window of opportunity is open.

WE NEED AN INFUSION OF CAPITAL TO MAKE IT HAPPEN.

Syringex is currently raising capital under a regulation D 506 private offering. If you are interested in participating, please contact: **Edward T. Whelan, Grace Holdings, Inc., Cellular: 732-319-9235**
Email: Ed@GraceHolding.com

RETURN ON INVESTMENT

THE COMPANY INTENDS TO FULFILL SHAREHOLDER VALUE IN THREE POSSIBLE WAYS:

1. Payment of dividends.
2. By bringing the Company into the public stock markets. The current PE ratio valuation of medical equipment and product companies is greater than 20 times earnings. If Syringex meets its \$25.7 million net earnings estimate for the 4th year of sales; and, if this multiple is maintained, our market cap would exceed \$1/2 billion. Anticipating about 20 million shares of stock outstanding at that time could realize a share price of ... well, you do the math.
3. Buyout by another company.

In Summary:

Current solutions are ineffective, expensive, and/or difficult to use. For years the market has been dominated by a few key players. Not because they had a superior product, but because they bought the market through key group purchasing organizations who controlled over 80% of the market. The market growth, relatively slow in the beginning, is finally speeding up because of public awareness, pressure from medical professionals, and the growing body of legislation. The awareness on the international scene has peaked and massive drives are in progress in countries throughout the world. I'd like to end on a quote from the Frost & Sullivan June 2003 report on the safety syringe market.

“End users are demanding safety devices that are simple to use and require no training. Manufacturers are challenged to develop a low cost, retracting needle syringe design. It would take a technological breakthrough to develop a safety device with comparable costs of conventional devices”.

Syringex has that technological breakthrough now; and we're inviting you to participate. The timing could not be better.

Syringex Management and Board Résumé's Page

Dr. Robert J. Wilkins, Director	9
John Jones, President/COB	10
Dr. Randall Watt, Vice President Sales/Marketing, Director	11
Dr. Vincent J. Giovinazzo, Director	12
Vicky Costello, General Manager	12
Gerard B. Selin, Advisory Committee	13
Dr. William B. Head, Jr., Advisory Committee	13
Robert Alan Bruce, Advisory Committee, Director	14
Robert Kevin Beauregard, Director	16
William Schult, Advisory Committee	16
Legal and Accounting Advisors	16

Syringex Executive Management Team

Dr. Robert J. Wilkins, Director/Chairman of Advisory Committee.

Started Syringex after working in the field of veterinary diagnostic laboratory services for 28 years. Coupled with extensive knowledge in running a large laboratory operation and being involved in developing unique diagnostic products, Dr. Wilkins is ideally prepared to run Syringex. Dr. Wilkins graduated from the University of Sydney (Australia) with a degree in Veterinary Medicine and a postgraduate degree in veterinary diagnostic pathology.

Having worked in the medical laboratory field including handling contagions and medical waste Dr. Wilkins became aware of the urgent need to create safer medical products that could reduce the risk of exposure of potential pathogens to health care workers. When presented by the inventors with the safety syringe he proceeded with the assistance of Mr. Kading and Mr. Selin to form Syringex Medical, Inc. and to develop this product for commercial use.

Dr. Wilkins moved from Australia to the US in 1970 to become head of clinical pathology at the Animal Medical Center in NYC. Board certified in pathology in 1976 he started a diagnostic lab for veterinarians in private practice. By 1994 when sold this lab had expanded to serve over 1200 veterinary accounts and had annual sales in excess of \$7 million. During this time he established a medical waste disposal company and business management company. He developed several unique commercial diagnostic tests for animals. He currently is a senior staff veterinary animal pathologist for Antech Diagnostic and has acted as President and CEO of Syringex Medical, Inc.

1968-1970 - General Practice - Relief Veterinarian, Sydney Australia.

1970-1972 - Resident, Clinical Pathology - Animal Medical Center NYC, NY

1974 - Licensed to Practice Veterinary Medicine NJ License # 1671

1975 - President, American Society for Veterinary Clinical Pathology

1976 - Board Certified Veterinary Pathology, specialty Clinical Pathology

1973 -1988 - Staff Clinical Pathologist - Animal Medical Center, NYC, NY

1978 - 1994 - President and Director of Cenvet Laboratory Inc., a private veterinary diagnostic laboratory serving over 2000 practices in the Eastern Region of the USA.

1994 - 1998 - Consultant, Veterinary Clinical Pathologist, Antech Diagnostics, Farmingdale, NY

1999 - present - Staff Veterinary Clinical Pathologist, Antech Diagnostics, Farmingdale, NY

1994 - present - President of R&B Management, Consulting firm. Rejuvenation Inc. (General Health Care), Resource Biomedical Corp. (Diagnostic devices)

1998- present - CEO, Syringex Medical Inc. (Medical Device company)

John O. Jones, Jr., President/Treasurer/Chairman of the Board.

Mr. Jones has had extensive hands on experience with all phases of design, development, production, administration, marketing, and sales. A successful turnaround consultant. Started and ran several successful companies, private and public, in the U.S., Mexico and Pacific Rim. 3 U.S. patents and 1 Canadian patent. Mr. Jones' formal education has centered on math, physics, electronic engineering, production engineering, computer science, and business law.

7-2003 to Present – President/Chairman of the Board, Syringex Medical, Inc.

6-2000 to 7-2003 - Executive Vice President, COO, Syringex Medical, Inc.

Re-designed single-use, anti-stick safety syringe to make reliable and bring in at lower cost. Designed to comply with ISO and FDA specs, prepared all documentation for 510(k) and received clearance from FDA. Designed tooling and set up bench testing procedures. Presently reviewing offshore assembly setup.

1-97 to 6-2000 – President, Global Stock Exchange

Founded internet company to provide a forum for mergers, acquisitions and taking companies public.

6-91 to 6-98 – President, Pulse Technology, Inc.

Research and development for a line of products for the early detection and tracking of cardio/pulmonary disease. Products ready to go into silicon chip design phase.

2-91 to 4-91 – President, Rausch Company

Reorganized the military and high reliability contract assembly company, identified new markets and prepared company for sale.

2-90 to 2-91 - Consulting Engineer, American National

Redesigned heater products and obtained UL approval. Set up ongoing in-house U.L. compliance procedures. Modified manufacturing processes, wrote assembly manuals, and trained production and supervisory staff.

11-88 to 2-90 - Vice President Technology and Development, JMP Industries, Inc.

Reviewed projects, reduced costs by becoming involved in or supervising design or redesign of customer products, and set up manufacturing facilities and assembly procedures in U.S., Mexico, and Orient. Heavily involved in company reorganizations.

4-88 to 11-88 - Director of Research and Development, Dermanetics, Inc. Headed team that designed the first computerized low pressure bed for burn patients and treatment of pressure sores. Built prototypes, and established manufacturing criteria.

1-87 to 4-88 - Independent contractor Designed a proportional, tri-state heater control and set up production facility in Mexico. Designed new concept in self regulating heating pad to eliminate burn outs. Designed TV Butler, a consumer clock to turn off unattended television sets, and set up manufacturing in Hong Kong. Designed point of purchase control circuit for heating system. Designed a new concept of self regulating heat controls for motors and transformers. Developed system to eliminate salt build up in water pipes and increase efficiency of reverse osmosis water purification systems (some possible future application in treatment of bone spurs, stones, and arterial plaque).

1-76 to 1-87 – President, EDDE, Inc. Santa Ana, CA

Administration, general management. Research and development, market analysis, product generation, set up production facilities in the U.S., Mexico, the Pacific Rim, and China, quality analysis, quality control, and failure analysis. Established budgets and budget controls, approved expenditures, controlled purchasing, negotiated contracts with vendors and distributors, wrote business and marketing plans and operations manuals, and secured financing.

Controlled a number of different projects as primary engineer and/or project coordinator including various consumer and medical products, a line of clocks and massage systems, a computer controlled exhibit locator for the L. A. Convention Center, a phone monitoring system, and a subcutaneous electroneural stimulator for UCLA Medical Center as part of protocol to stimulate endorphin and enkephalin release for

control of chronic pain.

Other Designs - A medical lamp for treatment of acne, wrinkles, and hair loss. Set up production in mainland China. Reduced total production cost by 67%. A force platform to monitor and record weight shift during a golf swing. The units utilized solid-state pressure sensors and aircraft type honeycomb platform elements. A tri-state heater control. Built the first 150,000 units in house. Had only one field failure. Set up a manufacturing facility in Mexico for ongoing production. A preamp and power supply for stereo audio that far surpassed all commercial preamps for separation, response, and dynamic range. A greenhouse control to monitor and control temperature, humidity, watering, and light cycles. Redesigned medical cold packs to keep them from forming salt crystals. Extended the life of the product over 1000% by reformulating their gel and creating a new PVC draping process to reduce vapor transmission loss.

Dr. Randall Watt, Vice President Sales/Marketing/director/Advisory Committee.

Doctor of Pharmacy (PharmD) - University of Arkansas – Little Rock, AR – 2001

A business professional with twenty plus years of progressive experience in operations, contract development, distribution, regulatory compliance, and marketing. Primary strengths include strategic planning and organization, building and maintaining strong customer relationships, and solidifying the customer base as well as team building. Instrumental in developing a profitability worksheet program that enabled the company to attain a better understanding of profitability within individual business units. Regarded as an innovative problem solver and a team player.

2002 – Present - Vice President of Production, Regional Nuclear Pharmaceuticals, Inc., Birmingham, AL
Responsible for hiring all personnel to operate cyclotron sites, and maintaining efficiency of site operations to meet regulatory and market demands, while participating in the expansion efforts of a small, young and growing company for purposes of participating in the positron emission tomography (PET) market.

1991 – 2001 - Senior Market Manager, Mallinckrodt Inc., St. Louis, MO

Responsible for developing profitability program to improve market analysis on a business unit level. Develop and maintain pricing guidelines for all US nuclear medicine business. Develop a customer hierarchy system for product allocation during times of product shortages. Analyze current product portfolio and guide manufacturing in product deletions and additions.

1997-1999 - Director of Pharmacy Practice, Mallinckrodt Inc., St. Louis, MO

Responsible for evaluating new procedures for improving product utilization, developing new/improved distribution containers, oversee pharmacy operations during transition of upper management.

1991 -1997- Market Manager, Mallinckrodt Inc., St. Louis, MO

Responsible for company-owned pharmacy expansion, manage relationships with independent pharmacy partners, and gain access to proprietary products from competitor companies.

1990 – 1991 - Nuclear Pharmacy Manager, Mallinckrodt Medical, St. Paul, MN

1987 - 1990 - Nuclear Pharmacy Manager, Mallinckrodt Medical, Dallas, TX

1984 - 1987 - Staff Radiopharmacist, Mallinckrodt Medical, Dallas, TX

1982 - 1984 - Staff Radiopharmacist, Nuclear Pharmacy, Inc., Orlando, FL

1981 - 1982 - Staff Pharmacist, Eckerd Drugs, Orlando, FL

1978 - 1980 - Staff Pharmacist, Eckerd Drugs, Orlando, FL

Vincent J. Giovinazzo, M.D., Director

Dr. Giovinazzo graduated from Princeton University in 1973 with an A.B. in Biology. He then attended the New Jersey Medical School at the University of Medicine and Dentistry of New Jersey and graduated in 1977 at the top of his class. After an internship at St. Vincent's Medical Center in Manhattan, he completed a dermatology residency as a commissioned officer in the United States Public Health Service, in a combined program at the U.S.P.H.S. Hospital on Staten Island and at the Columbia-Presbyterian Hospital in Manhattan. He began a residency in ophthalmology in 1981 at the Manhattan Eye Ear and Throat Hospital and was chief resident and completed the program 1984. He undertook a glaucoma fellowship from 1984 to 1985 in a combined program at the Manhattan Eye, Ear and Throat Hospital and the Columbia-Presbyterian Hospital. He then completed a retinal fellowship at the Manhattan Eye, Ear and Throat Hospital from 1985 to 1986. He is board certified in both dermatology and ophthalmology. Dr. Giovinazzo is currently the Director of Ophthalmology at the Staten Island University Hospital and is

an attending physician at the Manhattan Eye, Ear and Throat Hospital. He was appointed by the Governor of New York State to the Medical Advisory Board of the New York State Athletic Commission. He is an Assistant Professor of Ophthalmology at the State University of New York Health Science Center in Brooklyn. He has written numerous scientific articles in fields of dermatology and ophthalmology.

1969-1973 - Undergraduate degree in biology at Princeton University

1973-1977 - New Jersey Medical School, M.D. degree, graduated first in class

1977-1978 - Internship at St. Vincent's Hospital and Medical Center in Manhattan

1978-1981 - Residency in Ophthalmology in U.S.P.H.S. Hospital on Staten Island and Columbia Presbyterian Hospital in Manhattan

1981-1984 - Residency in ophthalmology at the Manhattan Eye Ear and Throat Hospital in Manhattan, Chief Resident third year

1984-1985 - Fellowship in Glaucoma and Manhattan Eye Ear and Throat Hospital and Columbia Presbyterian Hospital in Manhattan

1985-1986 - Fellowship in Retina at the Manhattan Eye Ear and Throat Hospital in Manhattan

1986 -Present - Ophthalmology practice in Manhattan and Staten Island

1990- Present - Clinical Assistant Professor of Ophthalmology State University of New York Health Science Center at Brooklyn

1990 -Present - Director of Ophthalmology, Staten Island University Hospital

Vicky Costello, General Manager.

Vicky is a seasoned credit/office manager, controller, and sales administrator. She has had extensive experience working with import and export on a large scale. Vicky has interfaced with major accounts and has maintained human resources within the companies she has been associated with.

1991-2002 - Credit Manager/Office Manager, Arbek Manufacturing Inc., Chino, CA

Managed all phases of credit from opening accounts, setting credit limits, through the resolution of problems to collection. Annual sales of \$27 million. Average terms of Net 30 with DSO of 34.

Major Accounts included Sears, J.C.Penney, Wickes. Interfaced with all departments. Established policies and procedures. Prepared final commission statements monthly for each sales representative.

1986-1990 - Sales Administrator, American National Watermattress, Anaheim, Ca

Supervised inside sale department and customer service. Maintained inventory levels for 5 remote out of state warehouses. Responsible for house accounts, private label customers, foreign accounts and special projects. Attended and assisted in setting up Trade Shows.

1980-1986 - Assistant Controller. American National Watermattress, Anaheim, Ca

Responsible for all accounting functions through Financial Statements. Supervised in-house HR and processed payroll and payroll tax return for approx. 300(varied). Sales tax returns for multi states.

Additional Experience: Banking, Travel Industry, Notary

Advisory Committee

Gerard B. Selin, Advisory Committee.

In 1948 Mr. Selin co-founded EVSO Pharmaceutical that marketed a wide range of pharmaceuticals and diagnostic devices to veterinarians throughout the US. In 1975 this company was sold and Mr. Selin formed Avimark, Inc. to develop and market products to the veterinary profession.

In 1982 Mr. Selin was hired by Henry Schein, Inc. as vice president of both the Veterinary and New Business and Acquisition Divisions. His success in expanding these divisions led to his promotion in 1985 to Vice Chairman of the Veterinary Products Division. One of his most notable successes was the development and marketing of a product line especially designed for veterinary dentistry. During his time at Henry Schein revenues for the veterinary market rose from less than \$1 million to over \$80 million annually.

Mr. Selin resigned in 1992 to become an independent marketing consultant. He helped form Syringex

Medical, Inc. after being shown the safety syringe device by the inventor.
1998 to present - Vice-President and Secretary to Syringex Medical, Inc.
1992 to present - Marketing Consultant.
1990 to 1992 - Henry Schein, Inc. Vice-Chairman Veterinary Products Division.
1985 to 1990 - Henry Schein, Inc. Vice-President Veterinary Division, Vice-President of New Business Acquisitions.
1982 to 1985 - Henry Schein, Inc. General Manager and Director of Marketing, Veterinary Division.
1978 to 1981 - Avimark, Inc. President. Developed all marketing programs.
1975 to 1978 - Marketing Consultant.
1948 to 1975 - EVSCO Pharmaceutical Co., Inc. Officer and Director. Developed all marketing programs.

William B. Head, Jr., M.D., Advisory Committee

Professional Societies

Fellow, American Academy of Neurology
Member, American Psychiatric Association
Member, American Medical Association
Member, Medical Society of the State of New York
Member, Medical Society State of New Jersey
Member, Richmond County Medical Society
Member, Union County Medical Society
Fellow, Academy of Medicine of Richmond
Member, Los Angeles County Medical Association

Education

B.A. (Cum Laude) 1966 - Harvard University
M.D., 1970 - University of Southern California

Postdoctoral Training

1970-1971, Internship, St. Vincent's Hospital, Staten Island, New York.
1971-1974, Psychiatry Residency, Columbia. Presbyterian Medical Center, New York, NY
1974-1976, Neurology Residency, Mt. Sinai Hospital, New York., New York

Institutional Affiliations

July 1, 1982, Beth Israel Medical Center, New York
1987, Hospital of the Good Samaritan, California

Certification

American Board of Psychiatry and Neurology, Diplomat in Psychiatry, 1975
American Board of Psychiatry and Neurology, Diplomat in Neurology, 1983
1970, New York License
1971, New Jersey License
1978, California License
1986, Massachusetts License

Miscellaneous

Independent Medical Examiner, California Division of Industrial Relations - 1983 - 1993
Qualified Medical Examiner, State of California - 1983 - 1993
Medical Arbitrator, New York City Board of Education
Impartial Specialist, New York State
Workers' Compensation Board

Robert Alan Bruce, Advisory Committee

April 2002 to present - Self Employed. Operating a sole proprietorship with a variety of investment interests. Also assisting small business with technical and management consulting.

1997 to April 2002 - JDS Uniphase Corporation Nepean, ON. Director Optical Coating Group. Responsible for managing the development of the JDS Optical coating group to its current position as a supplier of thin film filters for DWDM products.

1994 - 1997 - Nortel, Nepean, ON. Manager InP Wafer processing Introduction to manufacturing of eight device products currently in use in Nortel transmission systems.

1985 –1994 – Nortel, Ottawa, ON. Member Scientific Staff. Process Development Engineer for InP Based Photonic devices.

These devices include InP based lasers and detectors for use in 2.4 and 10 Gb/s optical transmission systems.

Education

1983–1985 - McMaster University, Hamilton, ON. M.Eng. Metallurgical Engineering

1979–1983 - McMaster University, Hamilton, ON. B.Sc. Honours Metallurgy and Materials Science.

Patents and Publications

Two patents and 19 publications in refereed scientific journals.

Patents

Method of Reducing the Thermally Induced shift in the Emission Wavelength of Laser Diodes. U.S. patent 5,345,459, Sept. 6, 1994.

Method for enhancing strength and durability of an adhesive joint of ion-doped glass components

United States Patent Application 20030017346 , January 23, 2003

Publications

D.G. Ivey, D. Wang, D. Yang, R. Bruce, and G. Knight

“Au/Ge/Ni Ohmic Contacts to InP”, **Journal of Electronic Materials**, 1994,

Vol. 29, No. 5, pp. 441-446

L.E. Tarof, J. Yu, T. Baird, R. Bruce, and G. Knight

“Temperature Measurements of Separate Absorption, Grading, Charge and Multiplication (SAGCM) InP/InGaAs Avalanche Photodiodes”.

IEEE Photonics Letters, 1993, Vol. 5, No. 9, pp 1044-1046

D.G. Knight, W.T. Moore and R.A. Bruce

“Growth of Semi-Insulating InGaAsP Alloys Using Low Pressure MOCVD”.

Journal of Crystal Growth, 1992, Vol. 124, pp. 352-357.

P. Jian, D.G. Ivey and R.A. Bruce

“Au/Ge/Pd Ohmic Contacts to n-type InP”., presented at MRS Spring Meeting, San Francisco, April 26-May 1,

1992, published in **MRS Symposium proceedings**, Vol. 260, pp. 531-536.

D.G. Ivey, P. Jian L. Wan, R. Bruce, S. Eicher and C. Blaauw

“Pd/Zn/Pd/Pd/Au Ohmic Contacts to p-type InP”.

Journal of Electronic Materials, 1991, Vol. 20, pp. 237-246.

C. Wu, C. Rolland, R. Bruce, K.D. Chik, and J.M. Xu

“A Vertically Coupled InGaAs/InP Directional Coupler Filter of Ultranarrow Bandwidth”.

IEEE Photonics Technology Letters, 1991, Vol. 3 No. 6 pp. 516-517.

T.W. MacElwee, I.D. Calder, R.A. Bruce, and F.R. Shepherd

“High-Performance Fully Depleted Silicon on Insulator Transistors”.

IEEE Transactions on Electron Devices, 1990, Vol. 37 No. 6, pp. 1444-1451.

D.G. Ivey, P. Jian and R. Bruce

“An Investigation of Au-Mn Contacts to p-type InP”.

Thin Solid Films, 1990, Vol. 190, pp. 217-226.

D.G. Ivey, P. Jian, L. Wan and R. Bruce

“Reactions Between Pd Thin Films and InP”.

Journal of Electronic Materials, 1992, Vol. 21, No. 8, pp. 831-839.

R. Bruce, D. Clark and S. Eicher

“Low Resistance Pd/Zn/Pd/Au Ohmic Contacts to p-type GaAs”.

Journal of Electronic Materials, 1990, Vol. 19, No. 3, pp. 225-229.

C.M. Hurd, S.P. McAlister, W.R. McKinnon, M. Trudeau, D.J. Day, R.A. Bruce, T. Lester, and V. Ledlow

“Effect of Internal Resistance in GaAs/Al_xGa_{1-x}As Heterostructures with Parallel Conduction”.

Semiconductor Science and Technology, 1989, Vol. 4, pp. 168-176.

R.A. Bruce, W.T. Moore, T. Lester, D.A. Clark and A.J. SpringThorpe

“Secondary Ion Mass Spectrometry of Diffusion Under Ni/Ge/Au Ohmic contacts to n-type GaAs using a Lift-off Technique”.

Institute of Physics Conference Series, 1989, No. 10, Section 8, p 671.

P. Mandeville, A.J. SpringThorpe, C.J. Miner, R.A. Bruce, J.F. Currie, and S.P. McAlister

“Growth and Characterization of GaAs on Si Substrates Grown by Molecular Beam Epitaxy”.

Canadian Journal of Physics, 1987, Vol. 65, No. 8.

D. Ivey, R. Bruce, and G.R. Piercy

“Transmission/Scanning Transmission Electron Microscopy Investigation of Au/Cr Contacts to p-type InP”.

Solid State Electronics, 1988, Vol. 31, No. 8 pp 1251-1258.

R.A. Bruce, S. Eicher and W.D. Westwood

“Effects of Resputtering on the Composition of W_{Si} Films Deposited by MultiLayer Sputtering”.

Journal of Vacuum Science and Technology A, 6(3) May/June 1988.

R.A. Bruce and G.R. Piercy

“An Improved Ni-Ge-Au Ohmic Contact to n-type Ga As”.

Solid State Electronics, 1987, Vol. 30, No. 7 pp 729-737.

R.A. Bruce, P. Mandeville, A.J. SpringThorpe, and C.J. Miner

“TEM Characterization of the Defect Structure in GaAs Grown on Si Substrates by MBE”.

Inst. Phys Conf. Ser. No. 87, 1987, Section 2.

D. Egar, A.J. Spring/Thorpe, A. Margittai, F.R. Shepherd, R.A. Bruce, and G.M. Smith

“The Effect of Zn on InP Surfaces During Diffusion”.

Journal of Electronic Materials, 1987, Vol. 16, No. 3.

W.M. Lau, D. Hui, L. Young, R.A. Bruce

“A TEM and SIMS study of the Silicon Nitride/Gallium Arsenide Interface”.

Proceedings of the 11th International Congress on X-Ray Optics and Microanalysis, 1986, pp. 368-372.

Robert Kevin Beauregard, Director.

William Schult, Advisory Committee

Mr. Schult is currently manager with Schult Green Investment Capital, Inc., and investment management firm. Prior to that, he held various positions in banking, including the position of chief financial officer of various publicly owned banking organizations. He was also with the accounting firm of KPMG LLP and has experience as an independent business consultant. He received his BBA fro Hofstra University and is a CPA in New York State.

Syringex Legal and Accounting

Legal Advisor

Richard Feiner, Esq.

Of Counsel to: Silverman, Sclar, Byrne, Shin & Byrne P.C.

381 Park Avenue South

New York, NY 10016

(212) 779-8600

Accountant

Stewart Benjamin

Certified Public Accountant, P.C.

27 Shelter Hill Road

Plainview, NY 11803

(516) 933-9781